Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $952,000 Holdings in Zoetis Inc. $ZTS

Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 6.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,107 shares of the company’s stock after acquiring an additional 383 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Zoetis were worth $952,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its holdings in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares in the last quarter. Vest Financial LLC bought a new position in Zoetis during the 1st quarter valued at $207,000. Pines Wealth Management LLC boosted its holdings in Zoetis by 10.6% during the 1st quarter. Pines Wealth Management LLC now owns 2,601 shares of the company’s stock worth $428,000 after acquiring an additional 249 shares during the last quarter. Blue Zone Wealth Advisors LLC grew its stake in shares of Zoetis by 15.2% in the 1st quarter. Blue Zone Wealth Advisors LLC now owns 29,980 shares of the company’s stock worth $4,936,000 after acquiring an additional 3,948 shares in the last quarter. Finally, Stokes Capital Advisors LLC purchased a new stake in shares of Zoetis in the first quarter valued at about $4,658,000. 92.80% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ZTS. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Finally, Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Five equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and an average target price of $200.88.

Zoetis Trading Down 0.0%

NYSE:ZTS opened at $146.45 on Friday. Zoetis Inc. has a 12 month low of $139.34 and a 12 month high of $196.55. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The firm’s 50 day moving average is $149.79 and its 200 day moving average is $155.08. The stock has a market capitalization of $64.91 billion, a PE ratio of 25.21, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period last year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.